Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Savara Inc
(NQ:
SVRA
)
4.370
-0.040 (-0.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Savara Inc
< Previous
1
2
3
4
Next >
Savara Announces New Employment Inducement Grant
August 16, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
August 15, 2024
From
Savara Inc.
Via
Business Wire
SVRA Stock Earnings: Savara Misses EPS for Q2 2024
August 12, 2024
SVRA stock results show that Savara missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Savara Inc.
Via
Business Wire
SVRA Stock Earnings: Savara Misses EPS for Q1 2024
May 09, 2024
SVRA stock results show that Savara missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
SVRA Stock Earnings: Savara Beats EPS for Q4 2023
March 07, 2024
SVRA stock results show that Savara beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
June 28, 2024
From
Savara Inc.
Via
Business Wire
Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
June 26, 2024
Savara announces Phase 3 IMPALA-2 trial results for molgramostim in treating autoimmune pulmonary alveolar proteinosis. The inhaled GM-CSF met primary and secondary endpoints, showing significant...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
June 26, 2024
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!
Via
InvestorPlace
Savara Inc. (NASDAQ: SVRA) Making Surprising Moves in Monday Session
February 26, 2024
Via
Investor Brand Network
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
June 26, 2024
From
Savara Inc.
Via
Business Wire
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
June 25, 2024
From
Savara Inc.
Via
Business Wire
3 Penny Stocks Poised for Major Upside Over the Next 5 Years
June 19, 2024
These three penny stocks to buy are poised for major upside over the medium-term, for various reasons worth exploring.
Via
InvestorPlace
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
June 11, 2024
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year.
Via
InvestorPlace
Savara to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Savara Inc.
Via
Business Wire
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
May 19, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces New Employment Inducement Grant
May 16, 2024
From
Savara Inc.
Via
Business Wire
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present at the Citizens JMP Life Sciences Conference
May 07, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
April 08, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces New Employment Inducement Grant
March 22, 2024
From
Savara Inc.
Via
Business Wire
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
March 07, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
March 06, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces New Employment Inducement Grant
February 02, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present at Two Upcoming Healthcare Conferences
January 31, 2024
From
Savara Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 16, 2024
Via
Benzinga
Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday
January 02, 2024
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 200 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
December 21, 2023
From
Savara Inc.
Via
Business Wire
Savara Added to the NASDAQ Biotechnology Index
December 20, 2023
From
Savara Inc.
Via
Business Wire
Savara Announces New Employment Inducement Grant
December 15, 2023
From
Savara Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.